Insights

345 Park Avenue South

Xchange Challenge

All floors are lab-ready and cabled for digital health.

Community

Residents

Leadership

Staff

Neighborhood

Be part of *Cure.*

Orange

Where scientists, entrepreneurs and visionaries converge.

Campus

Ecosystem

Event Spaces

Gallery

Networking hub

Space Availability

A place to *Succeed.*

Green

Joe Wilson How Life Sciences Companies Use AI to Target Investors Mega Menu Image 

Critical Discussions Advancing Healthcare

Events

Event Inquiry

Past Events

Speakers

Tuesday Talks

Cure *Events.*

Magenta

Cure Clips

Tuesday Talks Series

Cure *Tuesday Talks*

Award Finalists to be announced soon!

Partnerships and Sponsorships

Women in Science

XSeed Award

Connect with *Opportunity.*

Blue

Network

Cure Insights Article A Bionic Pancreas that will Help Parents Sleep More Peacefully image for Cure Insights Mega Menu.  Image credit Cottonbro Studio.

A Bionic Pancreas that will Help Parents Sleep More Peacefully

In-depth *Insights.*

About

Contact us

Having returned to private practice, Anna Aryankalayil, JD, focuses on merger clearance and litigation, government conduct investigations, and antitrust counseling and compliance.

During her time at the FTC from March 2020 to September 2022, Aryankalayil advised on merger and anticompetitive conduct investigations and enforcement actions across a wide range of sectors, including tech, pharmaceutical and life sciences, healthcare, defense, oil &amp; gas, retail, and consumer goods. She also advised on litigation and appellate strategy, the FTC’s advocacy through amicus briefs, and other cutting edge competition policy matters, such as, merger policy, digital platforms, intellectual property, and nascent competition in innovative industries.

Prior to joining the FTC, Aryankalayil was a senior associate in private practice where she focused on antitrust litigation, government conduct investigations and compliance, and the antitrust aspects of mergers, acquisitions, and joint ventures.

Antitrust Partner at Herrington & Sutcliffe LLP

Join us at Cure on January 31 to hear from experts about prospects for exits in the coming year, and how to strategize what flavor of exit would be right for your company—an IPO, M&A, JV, or something else.

Will IPOs Return in 2024?